Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering
messenger RNA (mRNA) therapeutics and vaccines, and Magenta
Investments, a leading pharmaceutical and healthcare company that
is part of an investment and industrial conglomerate in the United
Arab Emirates (UAE), today announced a new agreement to distribute
the Moderna COVID-19 Vaccine as well as Moderna’s updated variant
booster candidates, once authorized, in the UAE in 2021 and
2022.
“We welcome the opportunity to work alongside Magenta for the
distribution of our vaccine in the UAE,” said Corinne Le Goff,
Pharm.D., M.B.A., Chief Commercial Officer of Moderna. “Together
with our partners, we hope to advance our goal to expand access to
our vaccine globally, and support governments such as the UAE in
protecting their citizens, residents and visitors against the
pandemic.”
“As the world continues to endure the drastic impact of the
COVID-19 pandemic, we feel privileged to be taking part in the
global effort to enhance the protection of humanity by making
available this highly advanced vaccine in the United Arab Emirates.
Magenta is fully committed to supporting the efforts of the
government of the United Arab Emirates in its monumental efforts to
contain the pandemic,” said Dr. Zahid Al Sabti, Managing Director
of Magenta Investments. “I am delighted to see Magenta entering
this strategic partnership with Moderna and contributing to the
ongoing battle against the pandemic.”
About the Moderna COVID-19 Vaccine
The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19
encoding for a prefusion stabilized form of the Spike (S) protein,
which was co-developed by Moderna and investigators from the
National Institute of Allergy and Infectious Diseases’ (NIAID)
Vaccine Research Center. The first clinical batch, which was funded
by the Coalition for Epidemic Preparedness Innovations, was
completed on February 7, 2020 and underwent analytical testing; it
was shipped to the National Institutes of Health (NIH) on February
24, 42 days from sequence selection. The first participant in the
NIAID-led Phase 1 study of the Moderna COVID-19 Vaccine was dosed
on March 16, 63 days from sequence selection to Phase 1 study
dosing. On May 12, the U.S Food and Drug Administration granted the
Moderna COVID-19 Vaccine Fast Track designation. On May 29, the
first participants in each age cohort: adults ages 18-55 years
(n=300) and older adults ages 55 years and above (n=300) were dosed
in the Phase 2 study of the vaccine. On July 8, the Phase 2 study
completed enrolment.
Results from the second interim analysis of the NIH-led Phase 1
study of the Moderna COVID-19 Vaccine in the 56-70 and 71+ age
groups were published on September 29 in The New England Journal of
Medicine. On November 30, 2020, Moderna announced the primary
efficacy analysis of the Phase 3 study of the vaccine conducted on
196 cases. On November 30, 2020, the Company also announced that it
filed for Emergency Use Authorization with the U.S. FDA and a
Conditional Marketing Authorization (CMA) application with the
European Medicines Agency. On December 18, 2020, the U.S. FDA
authorized the emergency use of the Moderna COVID-19 Vaccine in
individuals 18 years of age or older. Moderna has received
emergency (or other conditional, interim or provisional)
authorization for use of its COVID-19 vaccine in adults from health
agencies in Canada, Israel, the European Union, the United Kingdom,
Switzerland, Singapore, Qatar, Taiwan, the Philippines, Thailand,
Brunei, Paraguay, Japan, South Korea, Botswana and an Emergency Use
Listing (EUL) from the World Health Organization (WHO).
Initial data from Moderna’s Phase 2 study in the U.S. showed
that a single 50 µg dose of mRNA-1273 or mRNA-1273.351 given as a
booster to previously vaccinated individuals increased neutralizing
antibody titer responses against SARS-CoV-2 and two variants of
concern, B.1.351 (first identified in South Africa) and P.1 (first
identified in Brazil). A booster dose of mRNA-1273.351, the
Company’s strain-matched booster, achieved higher neutralizing
antibody titers against the B.1.351 variant of concern than a
booster dose of mRNA-1273. Safety and tolerability profiles
following third dose booster injections of 50 µg of mRNA-1273 or
mRNA-1273.351 were generally comparable to those observed after the
second dose of mRNA-1273 in the previously reported Phase 2 and
Phase 3 studies. A manuscript describing these preliminary results
was submitted as a preprint to medRxiv and will be submitted for
peer-reviewed publication upon completion of the multivalent
mRNA-1273.211 booster arm.
About Moderna
In 10 years since its inception, Moderna has transformed from a
science research-stage company advancing programs in the field of
messenger RNA (mRNA), to an enterprise with a diverse clinical
portfolio of vaccines and therapeutics across six modalities, a
broad intellectual property portfolio in areas including mRNA and
lipid nanoparticle formulation, and an integrated manufacturing
plant that allows for both clinical and commercial production at
scale and at unprecedented speed. Moderna maintains alliances with
a broad range of domestic and overseas government and commercial
collaborators, which has allowed for the pursuit of both
groundbreaking science and rapid scaling of manufacturing. Most
recently, Moderna’s capabilities have come together to allow the
authorized use of one of the earliest and most-effective vaccines
against the COVID-19 pandemic.
Moderna’s mRNA platform builds on continuous advances in basic
and applied mRNA science, delivery technology and manufacturing,
and has allowed the development of therapeutics and vaccines for
infectious diseases, immuno-oncology, rare diseases, cardiovascular
diseases and auto-immune diseases. Today, 24 development programs
are underway across these therapeutic areas, with 14 programs
having entered the clinic. Moderna has been named a top
biopharmaceutical employer by Science for the past six years. To
learn more, visit www.modernatx.com.
About Magenta
Magenta is the healthcare arm of a leading UAE investment and
industrial conglomerate with a diverse portfolio across multiple
sectors. Magenta is strongly focused on developing unique strategic
partnerships within the pharmaceutical and healthcare services
sectors and is committed to offering unique novel therapies and
technologies. With a dynamic leadership team and an innovative
business model, the company is dedicated to being a major regional
player in enhancing health and transforming care delivery through
advanced technology across the Middle East & Africa.
Magenta Investments is a part of Mawarid Holding Investment and
the Emirates Business Group, renowned business conglomerates in the
UAE.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including regarding: the Company’s development of
a vaccine to protect against the SARS-CoV-2 virus (mRNA-1273, also
referred to as the Moderna COVID-19 Vaccine); the Company’s plans
to obtain regulatory approval for the Moderna COVID-19 Vaccine in
the United Arab Emirates; and to distribute the Moderna COVID-19
Vaccine and updated booster candidates through Magenta Investments
in the United Arab Emirates and the timing for that distribution.
The forward-looking statements in this press release are neither
promises nor guarantees, and you should not place undue reliance on
these forward-looking statements because they involve known and
unknown risks, uncertainties, and other factors, many of which are
beyond Moderna’s control and which could cause actual results to
differ materially from those expressed or implied by these
forward-looking statements. These risks, uncertainties, and other
factors include those other risks and uncertainties described under
the heading “Risk Factors” in Moderna’s most recent Annual Report
on Form 10-K filed with the U.S. Securities and Exchange Commission
(SEC) and in subsequent filings made by Moderna with the SEC, which
are available on the SEC’s website at www.sec.gov. Except as
required by law, Moderna disclaims any intention or responsibility
for updating or revising any forward-looking statements contained
in this press release in the event of new information, future
developments or otherwise. These forward-looking statements are
based on Moderna’s current expectations and speak only as of the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210615005801/en/
Moderna: Media: Colleen Hussey Director, Corporate
Communications 617-335-1374 Colleen.Hussey@modernatx.com
Investors: Lavina Talukdar Senior Vice President & Head
of Investor Relations 617-209-5834
Lavina.Talukdar@modernatx.com
Magenta Media: communications@magenta-investments.com
+971 54 471 4903
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Sep 2023 to Sep 2024